QIAGEN N.V. appointed Jonathan M. Pratt as Chief Executive Officer, effective September 1, 2026, succeeding Thierry Bernard who stepped down from the Managing Board. Pratt brings over 25 years of leadership experience in life sciences and laboratory technologies, most recently serving as CEO of Filtration Group until its sale to Parker-Hannifin Corporation in August 2026. The Supervisory Board selected Pratt for his global industry knowledge and proven track record of improving performance. Bernard will support an orderly transition through the end of the year. QIAGEN reaffirmed its outlook for the third quarter and full-year 2026 while continuing a strategic review with independent advisors to create shareholder value. QIAGEN operates in the life sciences and molecular diagnostics industry, providing sample-to-insight solutions for extracting and analyzing molecular information from biological samples.

QIAGEN N.V. held its Annual General Meeting on June 24, 2026, where shareholders approved a cash dividend of $0.35 per ordinary share for 2026, totaling approximately $72 million gross. The meeting also authorized the Managing Board to implement a synthetic share repurchase program with a maximum aggregate repayment amount of $200 million. This mechanism involves increasing par value, consolidating shares via a reverse stock split ratio determined by management, and reducing par value to repay capital. Additionally, shareholders reappointed eight Supervisory Directors including new member Robert McMahon, reappointed Managing Directors Thierry Bernard and Roland Sackers, approved an amendment to the executive remuneration policy, and renewed share repurchase authorizations up to 10% of issued capital. QIAGEN N.V. operates in the life sciences industry, providing sample-to-insight molecular diagnostics solutions.

QIAGEN N.V. filed its U.S. GAAP quarterly report for the period ended June 30, 2026. For the six months ended June 30, net sales increased to $1,027.4 million from $1,017.0 million, while net income declined to $171.4 million from $187.0 million. The company declared a cash dividend of $0.35 per share for the quarter ended June 30, 2026, compared to $0.25 per share in the prior year period. Additionally, QIAGEN executed capital repayments totaling $496.9 million during the first half of 2026, reducing its common shares outstanding from 217.7 million to 206.8 million. The company operates in the life sciences industry, providing sample and assay technologies for molecular diagnostics.

QIAGEN N.V. reported unaudited second quarter 2026 results on August 5, 2026, with net sales of $535 million, unchanged from the prior year period and exceeding guidance for a 2% decline. Adjusted diluted earnings per share reached $0.62, surpassing the outlook of at least $0.60, while adjusted operating income margin held steady at 29.4%. The company reaffirmed its full-year 2026 outlook for net sales growth of approximately 1-2% and adjusted diluted EPS of at least $2.43 on a constant currency basis. QIAGEN also announced a 40% increase in its annual dividend compared to 2025 levels, with the payment made in July 2026. The company operates in the life sciences and molecular diagnostics industry, providing sample-to-insight solutions for extracting and analyzing biological information.